These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 23060048

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
    Konecny GE, Kolarova T, O'Brien NA, Winterhoff B, Yang G, Qi J, Qi Z, Venkatesan N, Ayala R, Luo T, Finn RS, Kristof J, Galderisi C, Porta DG, Anderson L, Shi MM, Yovine A, Slamon DJ.
    Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
    [Abstract] [Full Text] [Related]

  • 4. FGFR2 as a molecular target in endometrial cancer.
    Byron SA, Pollock PM.
    Future Oncol; 2009 Feb; 5(1):27-32. PubMed ID: 19243295
    [Abstract] [Full Text] [Related]

  • 5. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, Miura A, Sagara T, Ito S, Ohsawa H, Otsuki S, Funabashi K, Yashiro M, Matsuo K, Yonekura K, Hirai H.
    Cancer Res; 2020 Nov 15; 80(22):4986-4997. PubMed ID: 32973082
    [Abstract] [Full Text] [Related]

  • 6. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.
    Packer LM, Geng X, Bonazzi VF, Ju RJ, Mahon CE, Cummings MC, Stephenson SA, Pollock PM.
    Mol Cancer Ther; 2017 Apr 15; 16(4):637-648. PubMed ID: 28119489
    [Abstract] [Full Text] [Related]

  • 7. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM.
    Cancer Chemother Pharmacol; 2013 May 15; 71(5):1315-23. PubMed ID: 23468082
    [Abstract] [Full Text] [Related]

  • 8. Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression.
    Mori M, Mori T, Yamamoto A, Takagi S, Ueda M.
    Hum Cell; 2019 Jul 15; 32(3):367-378. PubMed ID: 30963412
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.
    Taurin S, Yang CH, Reyes M, Cho S, Coombs DM, Jarboe EA, Werner TL, Peterson CM, Janát-Amsbury MM.
    Int J Gynecol Cancer; 2018 Jan 15; 28(1):152-160. PubMed ID: 28953502
    [Abstract] [Full Text] [Related]

  • 11. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
    Kwak Y, Cho H, Hur W, Sim T.
    Mol Cancer Ther; 2015 Oct 15; 14(10):2292-302. PubMed ID: 26294741
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.
    Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, Goodfellow PJ, Pollock PM.
    Cancer Res; 2008 Sep 01; 68(17):6902-7. PubMed ID: 18757403
    [Abstract] [Full Text] [Related]

  • 13. Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.
    Packer LM, Stehbens SJ, Bonazzi VF, Gunter JH, Ju RJ, Ward M, Gartside MG, Byron SA, Pollock PM.
    Mol Oncol; 2019 Apr 01; 13(4):738-756. PubMed ID: 30537101
    [Abstract] [Full Text] [Related]

  • 14. Autocrine Prolactin Stimulates Endometrial Carcinoma Growth and Metastasis and Reduces Sensitivity to Chemotherapy.
    Ding K, Yuan Y, Chong QY, Yang Y, Li R, Li X, Kong X, Qian P, Xiong Z, Pandey V, Ma L, Wu Z, Lobie PE, Zhu T.
    Endocrinology; 2017 Jun 01; 158(6):1595-1611. PubMed ID: 28204229
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.
    Gentilin E, Minoia M, Bondanelli M, Tagliati F, Degli Uberti EC, Zatelli MC.
    Endocrine; 2017 Jun 01; 56(3):621-632. PubMed ID: 27585662
    [Abstract] [Full Text] [Related]

  • 17. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
    Chell V, Balmanno K, Little AS, Wilson M, Andrews S, Blockley L, Hampson M, Gavine PR, Cook SJ.
    Oncogene; 2013 Jun 20; 32(25):3059-70. PubMed ID: 22869148
    [Abstract] [Full Text] [Related]

  • 18. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J.
    Clin Cancer Res; 2013 Jul 01; 19(13):3693-702. PubMed ID: 23658459
    [Abstract] [Full Text] [Related]

  • 19. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Jeske YW, Ali S, Byron SA, Gao F, Mannel RS, Ghebre RG, DiSilvestro PA, Lele SB, Pearl ML, Schmidt AP, Lankes HA, Ramirez NC, Rasty G, Powell M, Goodfellow PJ, Pollock PM.
    Gynecol Oncol; 2017 May 01; 145(2):366-373. PubMed ID: 28314589
    [Abstract] [Full Text] [Related]

  • 20. Utilization of unlabeled probes for the detection of fibroblast growth factor receptor 2 exons 7 and 12 mutations in endometrial carcinoma.
    Liu T, Willmore-Payne C, Wallander ML, Layfield LJ.
    Appl Immunohistochem Mol Morphol; 2011 Jul 01; 19(4):341-6. PubMed ID: 21285871
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.